secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041481
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports Q2 2023 net loss of $7.7M, cash $17.0M; positive INB-200 Phase 1 data
--------------------------------------------------------------------------------

- Net loss $7.7M ($0.27/sh) vs $7.2M ($0.38/sh) in Q2 2022; R&D expense $4.1M, G&A $3.6M.
- Cash $17.0M as of June 30, 2023, up from $10.9M on March 31, 2023.
- INB-200 Phase 1 data: 100% of treated GBM patients (n=8) exceeded median PFS; enrollment completion expected in 2023.
- INB-400 Phase 2 trial in GBM on track to initiate enrollment in H2 2023; primary endpoint overall survival.
- R&D day scheduled for October 12, 2023 in New York City; preclinical ovarian cancer data presented at ASGCT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000095017023041481/0000950170-23-041481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000095017023041481/inab-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer